Drugs / AGN-195263
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01633788 | Aug 2012 → Feb 2015 | eye adnexa disorder | Allergan | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02965846 | Dec 2016 → Jun 2017 | dry eye syndrome | Allergan | Terminated | No outcome recorded |
| Phase 3 | NCT02815293 | Sep 2016 → Jun 2017 | dry eye syndrome | Allergan | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-195263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02965846 ↗ |
| Route | Other | “instilled in each eye twice daily.” NCT01633788 ↗ |